This note is not part of the order, but is intended to indicate its general effect.
This order classifies the drug tapentadol as a class B3 controlled drug by including tapentadol in Part 3 of Schedule 2 of the Misuse of Drugs Act 1975 (the Act).
The classification follows recommendations to the Minister of Health by the Expert Advisory Committee on Drugs, which is established under section 5AA of the Act. The effect of classifying tapentadol as a class B controlled drug is to make it an offence punishable by a maximum term of imprisonment of 14 years to deal with tapentadol without authority, for example, by supplying, producing, or importing it. Its inclusion in Part 3 of Schedule 2 of the Act means that ministerial approval is not required for any authorised use of the drug for medical purposes.
This order comes into force on a date to be set by a commencement order made under section 4A(1) of the Act. That section provides that the commencement order may be made only after the House of Representatives has approved this order. Approval cannot be given until at least 28 days after the date on which this order is notified in the Gazette.